CCCC Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . C4 Therapeutics
CCCC Stock  USD 2.42  0.20  9.01%   
C4 Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing C4 Therapeutics' valuation are provided below:
Gross Profit
-75.4 M
Profit Margin
(2.60)
Market Capitalization
171.8 M
Enterprise Value Revenue
0.1738
Revenue
39.8 M
We have found one hundred twenty available fundamental measures for C4 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. Investors should ensure to validate all of C4 Therapeutics' latest performance against the performance from 2010 to 2025 to make sure the company is sustainable this quarter and beyond. As of July 23, 2025, Market Cap is expected to decline to about 306.4 M. In addition to that, Enterprise Value is expected to decline to about 245.7 M

C4 Therapeutics Total Revenue

32.55 Million

Check C4 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 230.2 K, Net Interest Income of 15.2 M or Interest Income of 15.2 M, as well as many indicators such as Price To Sales Ratio of 6.67, Dividend Yield of 0.0 or PTB Ratio of 1.21. CCCC financial statements analysis is a perfect complement when working with C4 Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with CCCC Stock
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

C4 Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets365.9 M349.6 M241.6 M
Slightly volatile
Short and Long Term Debt Total50 M65.8 M30.2 M
Slightly volatile
Other Current Liabilities16.3 M16.7 M9 M
Slightly volatile
Total Current Liabilities44.8 M45.2 M32.6 M
Slightly volatile
Other Liabilities14.4 M15.2 M57 M
Slightly volatile
Property Plant And Equipment Net47.6 M63.4 M32.1 M
Slightly volatile
Current Deferred Revenue19.1 M18.7 M21.2 M
Slightly volatile
Accounts Payable2.4 M1.3 M2 M
Slightly volatile
Cash68.2 M55.5 M59.7 M
Slightly volatile
Non Current Assets Total91.9 M91.8 M53.8 M
Slightly volatile
Non Currrent Assets Other4.5 M6.1 M3.4 M
Slightly volatile
Other Assets3.6 M5.5 M3.2 M
Slightly volatile
Cash And Short Term Investments258.3 M244.9 M137 M
Slightly volatile
Net Receivables2.9 M3.1 M50.8 M
Slightly volatile
Common Stock Shares Outstanding53.8 M69.4 M45.8 M
Slightly volatile
Liabilities And Stockholders Equity365.9 M349.6 M241.6 M
Slightly volatile
Non Current Liabilities Total93 M88.4 M157.8 M
Slightly volatile
Capital Lease Obligations44.9 M65.8 M27.9 M
Slightly volatile
Other Current Assets9.5 M9.8 M4.8 M
Slightly volatile
Total Liabilities125.5 M133.6 M189.6 M
Slightly volatile
Property Plant And Equipment Gross52.6 M72.6 M34.4 M
Slightly volatile
Total Current Assets274 M257.8 M187.9 M
Slightly volatile
Net Working Capital229.2 M212.6 M155.3 M
Slightly volatile
Short Term Debt12.1 M11.5 M3.3 M
Slightly volatile
Common Stock4.6 K7 K2.6 K
Slightly volatile
Property Plant Equipment10.6 M6.7 M15.9 M
Slightly volatile
Long Term Debt8 M8.3 M9.8 M
Slightly volatile
Common Stock Total Equity5.1 K5.8 K4.4 K
Slightly volatile
Short Term Investments157.8 M189.4 M190.2 M
Very volatile
Long Term Debt Total8 M8.3 M9.8 M
Slightly volatile
Capital Surpluse664.4 M792.6 M537.8 M
Slightly volatile
Deferred Long Term Liabilities31.2 M21.9 M44.8 M
Slightly volatile
Non Current Liabilities Other106.1 M101 M34 M
Slightly volatile
Short and Long Term Debt1.8 M2.1 M2.2 M
Slightly volatile

C4 Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income15.2 M14.4 M3.2 M
Slightly volatile
Depreciation And Amortization1.7 M1.8 M3.7 M
Very volatile
Selling General Administrative30.1 M42.1 M17.4 M
Slightly volatile
Total Revenue32.6 M35.6 M24.7 M
Slightly volatile
Other Operating Expenses124.1 M155.2 M75 M
Slightly volatile
Research Development93.6 M110.6 M57.4 M
Slightly volatile
Cost Of Revenue142.1 M135.4 M49.3 M
Slightly volatile
Total Operating Expenses124.1 M155.2 M75 M
Slightly volatile
Reconciled Depreciation1.8 M1.8 M1.5 M
Slightly volatile
Selling And Marketing Expenses6.2 M7 M7.6 M
Slightly volatile

C4 Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings10 M11.2 M12.2 M
Slightly volatile
Stock Based Compensation17.9 M29.7 M8.5 M
Slightly volatile
Begin Period Cash Flow90.5 M130 M50.1 M
Slightly volatile
Depreciation1.8 M1.8 M1.5 M
Slightly volatile
Other Non Cash Items979.5 K1 M2.4 M
Very volatile
Capital Expenditures171 K180 K2.2 M
Slightly volatile
Total Cash From Financing Activities70.2 M45.3 M43.8 M
Slightly volatile
End Period Cash Flow70.6 M58.9 M62.5 M
Slightly volatile
Change To Netincome36.2 M34.5 M10.7 M
Slightly volatile
Dividends Paid9.6 M10.8 M11.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.677.018121.142
Pretty Stable
Days Sales Outstanding30.2331.8185945
Slightly volatile
Stock Based Compensation To Revenue0.430.83360.2788
Slightly volatile
Capex To Depreciation0.09410.0991.5935
Slightly volatile
EV To Sales6.947.306319.9218
Pretty Stable
Payables Turnover76.9273.2630.2599
Slightly volatile
Sales General And Administrative To Revenue0.751.18380.6413
Slightly volatile
Research And Ddevelopement To Revenue2.373.10922.1817
Slightly volatile
Capex To Revenue0.00480.00510.1018
Slightly volatile
Cash Per Share3.913.53043.6098
Slightly volatile
Days Payables Outstanding3.834.0452.201
Pretty Stable
Current Ratio4.755.70575.4747
Pretty Stable
Receivables Turnover6.2411.47133.9147
Slightly volatile
Capex Per Share0.00250.00260.1164
Slightly volatile
Revenue Per Share0.80.5131.0259
Slightly volatile
Interest Debt Per Share0.810.94790.9823
Pretty Stable
Debt To Assets0.10.18810.1142
Slightly volatile
Days Of Payables Outstanding3.834.0452.201
Pretty Stable
Ebt Per Ebit1.080.87940.9743
Pretty Stable
Quick Ratio4.915.70575.5702
Slightly volatile
Net Income Per E B T1.111.00121.0229
Very volatile
Cash Ratio2.311.22851.8208
Slightly volatile
Days Of Sales Outstanding30.2331.8185945
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00281.1016
Slightly volatile
Fixed Asset Turnover1.050.56150.956
Pretty Stable
Debt Ratio0.10.18810.1142
Slightly volatile
Price Sales Ratio6.677.018121.142
Pretty Stable
Asset Turnover0.110.10180.1177
Slightly volatile

C4 Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap306.4 M322.5 M537.2 M
Pretty Stable
Enterprise Value245.7 M258.6 M500.4 M
Pretty Stable

CCCC Fundamental Market Drivers

Cash And Short Term Investments244.9 M

CCCC Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About C4 Therapeutics Financial Statements

C4 Therapeutics stakeholders use historical fundamental indicators, such as C4 Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in C4 Therapeutics' assets and liabilities are reflected in the revenues and expenses on C4 Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in C4 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue18.7 M19.1 M
Total Revenue35.6 M32.6 M
Cost Of Revenue135.4 M142.1 M
Stock Based Compensation To Revenue 0.83  0.43 
Sales General And Administrative To Revenue 1.18  0.75 
Research And Ddevelopement To Revenue 3.11  2.37 
Revenue Per Share 0.51  0.80 
Ebit Per Revenue(3.36)(3.53)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VALEVale SA ADR
EGYVaalco Energy
CMCSAComcast Corp
When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:
How To Invest In CCCC
Details
Is CCCC Stock a good investment?
Details
What is C4 Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.48)
Revenue Per Share
0.569
Quarterly Revenue Growth
1.382
Return On Assets
(0.20)
Return On Equity
(0.46)
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY